Veracyte Q1 Revenues Up 21 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market today a 21 percent increase in first quarter revenues on strong volume growth for its Afirma gene expression classifier test, which differentiates benign thyroid nodules from cancerous ones.

For the three-month period ended March 31, Veracyte's revenues rose to $13.6 million from $11.2 million, topping analysts' consensus estimate of $13.1 million. Driving the revenue jump was a 33 percent increase in Afirma test volume to 5,352.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.